WinstonWınston
Back
MacroGenics logo

MacroGenics

MGNX
25
Biotechnology · Healthcare
Exchange
NASDAQ
Winston Score
25
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Weak
Growth
Good
Cash Flow
Weak
Stability
Mixed
Valuation
Data not available
Track this stock — start free trial

Winston Score History

The full picture

MacroGenics is a biotechnology company that discovers and develops cancer-fighting drugs. Its main product is Margenza (margetuximab), a treatment for a type of breast cancer, which is sold to hospitals and oncology clinics in the United States. The company focuses on a technology platform called Fc Optimization, which is designed to make antibody-based medicines work better against tumors.

MacroGenics earns money through drug sales, as well as collaboration agreements and licensing deals with larger pharmaceutical companies. It operates primarily in the United States and is a small-cap company with a market value around $200 million. The high gross margin reflects the nature of drug sales, but the company is still spending more than it earns, running a significant operating loss. The biggest risk MacroGenics faces is its dependence on a limited number of products and partnerships — if pipeline drugs fail in clinical trials or collaborations fall apart, the company could struggle to fund its operations.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+47.6% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+154.4% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

12.1%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~13 months

$173M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Strong grower

MacroGenics is growing revenue at 48% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
0.0%
Thin — 0.0% gross margin
Profit after running costs
Operating Margin
-42.2%
Losing money on operations — -42.2%
Return on the money invested
ROCE
-52.3%
Weak — -52.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+2.3%
Nearly flat sales (+2.3% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
7/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-39.1%
Burning cash (-39.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.82
Moderate — manageable debt (0.82)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial